CPIX - CIK 0001087294
The table below shows CUMBERLAND PHARMACEUTICALS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $4.93M | -$612.19K | $6.09M | $8.45M | $6.34M | $5.42M |
| Capital expenditure | $97.90K | $66.46K | $281.27K | $102.15K | $103.53K | $140.82K |
| Investing cash flow | -$4.71M | $57.84K | -$105.69K | -$13.67M | -$501.89K | -$1.76M |
| Dividends paid | - | - | - | - | - | - |
CUMBERLAND PHARMACEUTICALS INC reported operating cash flow of $4.93M for fiscal year 2025. That is up 905.7% from -$612.19K in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $569.48K (FY 2016) to $4.93M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $263.48K | $579.05K | $740.53K | $1.05M | $1.39M | $1.85M |
| Financing cash flow | -$6.75M | $196.90K | -$7.42M | -$2.06M | -$3.55M | -$7.12M |